We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

129 hedge funds and large institutions have $2.4B invested in Loxo Oncology, Inc in 2017 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 49 increasing their positions, 24 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,075% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 4

267% more funds holding in top 10

Funds holding in top 10: 311 (+8)

113% more capital invested

Capital invested by funds: $1.12B → $2.4B (+$1.27B)

104% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 24

50% more funds holding

Funds holding: 86129 (+43)

63% less call options, than puts

Call options by funds: $2.09M | Put options by funds: $5.7M

Holders
129
Holders Change
+43
Holders Change %
+50%
% of All Funds
3.22%
Holding in Top 10
11
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+266.67%
% of All Funds
0.27%
New
47
Increased
49
Reduced
24
Closed
4
Calls
$2.09M
Puts
$5.7M
Net Calls
-$3.62M
Net Calls Change
-$3.62M
Name Holding Trade Value Shares
Change
Change in
Stake
HI
101
HBK Investments
Texas
$556K +$384K +6,933 New
Squarepoint
102
Squarepoint
New York
$525K +$363K +6,553 New
VIA
103
Vident Investment Advisory
Georgia
$474K +$327K +5,906 New
Legal & General Group
104
Legal & General Group
United Kingdom
$405K +$73.8K +1,332 +36%
Bank of America
105
Bank of America
North Carolina
$383K -$188K -3,387 -41%
JMPWA
106
JP Morgan Private Wealth Advisors
California
$377K +$260K +4,700 New
VEA
107
Virtus ETF Advisers
New York
$321K -$355K -6,399 -61%
Principal Financial Group
108
Principal Financial Group
Iowa
$294K +$203K +3,664 New
BFM
109
Boothbay Fund Management
New York
$280K +$193K +3,489 New
JRP
110
Jasper Ridge Partners
California
$277K +$192K +3,457 New
EMG
111
Ellington Management Group
Connecticut
$265K +$183K +3,300 New
Marshall Wace
112
Marshall Wace
United Kingdom
$233K +$161K +2,912 New
SG Americas Securities
113
SG Americas Securities
New York
$228K +$158K +2,847 New
ARTA
114
A.R.T. Advisors
New York
$208K +$144K +2,600 New
SO
115
STRS Ohio
Ohio
$200K -$1.46M -26,283 -91%
BNP Paribas Financial Markets
116
BNP Paribas Financial Markets
France
$180K +$122K +2,194 +4,388%
AIP
117
Ameritas Investment Partners
Nebraska
$141K +$23.2K +419 +31%
Barclays
118
Barclays
United Kingdom
$123K -$187K -3,372 -69%
CG
119
Cutler Group
California
$112K +$77.6K +1,400 New
Group One Trading
120
Group One Trading
Illinois
$96K +$66.5K +1,200 New
Canada Life
121
Canada Life
Manitoba, Canada
$80K
IUHSA
122
Itau Unibanco Holding S.A.
Brazil
$80K +$50.1K +904 +942%
PG
123
PEAK6 Group
Illinois
$41K +$28.1K +507 New
Creative Planning
124
Creative Planning
Kansas
$38K +$12.8K +231 +96%
FPFS
125
First Personal Financial Services
North Carolina
$32K

LOXO Hedge Fund Activity: Q2 2017 in Review

129 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q2 2017, worth a combined $2.4B — up 113% from $1.12B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new LOXO positions and 4 closed out — a net gain of 43 holders — while 49 added to existing stakes and 24 trimmed.

The largest buyer was OppenheimerFunds, opening a new position worth an estimated $36.5M. The largest seller was Victory Capital Management, cutting an estimated $29.5M.

  • 129 institutional investors held Loxo Oncology, Inc (LOXO) as of Q2 2017, up from 86 in Q1 2017.
  • Funds reported $2.4B of Loxo Oncology, Inc stock for Q2 2017, up 113% quarter-over-quarter.
  • 47 funds opened new Loxo Oncology, Inc positions in Q2 2017 and 4 closed out, a net change of +43 holders.
  • The largest Loxo Oncology, Inc buyer in Q2 2017 was OppenheimerFunds, an estimated $36.5M added.
  • The largest Loxo Oncology, Inc seller in Q2 2017 was Victory Capital Management, an estimated $29.5M sold.

Based on aggregated 13F filings for Q2 2017.